ArticleFrontiers in microbiology2018
Purification, Characterization and
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Antimicrobial Activity of a Polymyxin A-like Compound and Characterisation of the Cognate Biosynthetic Gene Cluster Within the Genome of the ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Repurposing flufenamic acid as a putative PmrB-directed adjuvant to restore colistin activity inMicrobiology spectrum · 2026Article
- Antibacterial and cytotoxic activity of bioactives from Paenibacillus dendritiformis isolated from Lonar Soda Lake, Maharashtra, India.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Article
- Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.Scientific reports · 2025Article
- The structure of lipopeptides impacts their antiviral activity and mode of action against SARS-CoV-2Applied and environmental microbiology · 2024Article
- Nosocomial Bacteria Inhibition with Polymyxin B: In Silico Gene Mining and In Vitro Analysis.Antibiotics (Basel, Switzerland) · 2024Article
- Alkyl deoxyglycoside-polymyxin combinations against critical priority carbapenem-resistant gram-negative bacteria.Scientific reports · 2024Article
- Lipid Microenvironment Modulates the Pore-Forming Ability of Polymyxin B.Antibiotics (Basel, Switzerland) · 2022Article
- Genome-guided purification and characterization of polymyxin A1 fromFrontiers in microbiology · 2022Article
- The Potential Antimicrobial Action of Human Mucin 7 15-Mer Peptide and Its Metal Complexes.International journal of molecular sciences · 2021Article
- Synergistic Activity of Capsaicin and Colistin Against Colistin-ResistantFrontiers in pharmacology · 2021Article
- In Vitro Evaluation of Antimicrobial Peptide Tridecaptin M in Combination with Other Antibiotics against Multidrug ResistantMolecules (Basel, Switzerland) · 2020Article
- Tridecaptin M, a New Variant Discovered in Mud Bacterium, Shows Activity against Colistin- and Extremely Drug-ResistantAntimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nosocomial infections caused by antibiotic-resistant Gram-negative pathogens are of grave concern today. Polymyxins are considered as the last resorts of therapy to treat these multi-drug resistant (MDR) bacteria. But their associated nephrotoxicity and neurotoxicity calls for the development of safer polymyxin therapy until novel and less toxic antibiotics are discovered. No other polymyxin molecule except polymyxin B and E (colistin) is explored thoroughly in literature to demonstrate its clinical relevance. In the present study, we have isolated two antimicrobial compounds named P1 and P2 from the soil isolate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.